Mustafa Yaprak1, Mehmet Nuri Turan2, Ramazan Dayanan3, Selçuk Akın4, Elif Değirmen4, Mustafa Yıldırım5, Faruk Turgut6. 1. Division of Nephrology, Department of Internal Medicine, School of Medicine, Mustafa Kemal University, 31100, Antakya, Hatay, Turkey. mustafayaprakdr@yahoo.com. 2. Division of Nephrology, Department of Internal Medicine, School of Medicine, Harran University, Urfa, Turkey. 3. Department of Internal Medicine, Batman Regional State Hospital, Batman, Turkey. 4. Biochemistry, Batman Regional State Hospital, Batman, Turkey. 5. Division of Medical Oncology, Batman Regional State Hospital, Batman, Turkey. 6. Division of Nephrology, Department of Internal Medicine, School of Medicine, Mustafa Kemal University, 31100, Antakya, Hatay, Turkey.
Abstract
PURPOSE: Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were established showing the poor prognosis in some diseases, such as cardiovascular diseases and malignancies. The risk of mortality in patients with end-stage renal disease (ESRD) was higher than normal population. In this study, we aimed to investigate the relationship between NLR, PLR, and all-cause mortality in prevalent hemodialysis (HD) patients. METHODS: Eighty patients were enrolled in study. NLR and PLR obtained by dividing absolute neutrophil to absolute lymphocyte count and absolute platelet count to absolute lymphocyte count, respectively. The patients were followed prospectively for 24 months. The primary end point was all-cause mortality. RESULTS: Mean levels of neutrophil, lymphocyte, and platelet were 3904 ± 1543/mm(3), 1442 ± 494/mm(3), 174 ± 56 × 10(3)/mm(3), respectively. Twenty-one patients died before the follow-up at 24 months. Median NLR and PLR were 2.52 and 130.4, respectively. All-cause mortality was higher in patients with high NLR group compared to the patients with low NLR group (18.8 vs. 7.5 %, p = 0.031) and in patients with higher PLR group compared to patients with lower PLR group (18.8 vs. 7.5 %, p = 0.022). Following adjusted Cox regression analysis, the association of mortality and high NLR was lost (p = 0.54), but the significance of the association of high PLR and mortality increased (p = 0.013). CONCLUSION: Although both NLR and PLR were associated with all-cause mortality in prevalent HD patients, only PLR could independently predict all-cause mortality in these populations.
PURPOSE: Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were established showing the poor prognosis in some diseases, such as cardiovascular diseases and malignancies. The risk of mortality in patients with end-stage renal disease (ESRD) was higher than normal population. In this study, we aimed to investigate the relationship between NLR, PLR, and all-cause mortality in prevalent hemodialysis (HD) patients. METHODS: Eighty patients were enrolled in study. NLR and PLR obtained by dividing absolute neutrophil to absolute lymphocyte count and absolute platelet count to absolute lymphocyte count, respectively. The patients were followed prospectively for 24 months. The primary end point was all-cause mortality. RESULTS: Mean levels of neutrophil, lymphocyte, and platelet were 3904 ± 1543/mm(3), 1442 ± 494/mm(3), 174 ± 56 × 10(3)/mm(3), respectively. Twenty-one patients died before the follow-up at 24 months. Median NLR and PLR were 2.52 and 130.4, respectively. All-cause mortality was higher in patients with high NLR group compared to the patients with low NLR group (18.8 vs. 7.5 %, p = 0.031) and in patients with higher PLR group compared to patients with lower PLR group (18.8 vs. 7.5 %, p = 0.022). Following adjusted Cox regression analysis, the association of mortality and high NLR was lost (p = 0.54), but the significance of the association of high PLR and mortality increased (p = 0.013). CONCLUSION: Although both NLR and PLR were associated with all-cause mortality in prevalent HDpatients, only PLR could independently predict all-cause mortality in these populations.
Entities:
Keywords:
Hemodialysis; Inflammation; Mortality; Neutrophil-to-lymphocyte ratio; Platelet-to-lymphocyte ratio
Authors: Mi Ran Jung; Young Kyu Park; Oh Jeong; Jang Won Seon; Seong Yeob Ryu; Dong Yi Kim; Young Jin Kim Journal: J Surg Oncol Date: 2011-05-25 Impact factor: 3.454
Authors: Barbora Vozarova; Christian Weyer; Robert S Lindsay; Richard E Pratley; Clifton Bogardus; P Antonio Tataranni Journal: Diabetes Date: 2002-02 Impact factor: 9.461
Authors: David Wayne Johnson; Kathryn Joan Wiggins; Kirsten Anne Armstrong; Scott Bryan Campbell; Nicole Maree Isbel; Carmel Mary Hawley Journal: Kidney Int Date: 2005-02 Impact factor: 10.612
Authors: Adrian Vasile Mureșan; Eliza Russu; Emil Marian Arbănași; Réka Kaller; Ioan Hosu; Eliza Mihaela Arbănași; Septimiu Toader Voidăzan Journal: Biomedicines Date: 2022-05-29
Authors: Samantha E Halpern; Dimitrios Moris; Brian I Shaw; Madison K Krischak; Danae G Olaso; Samuel J Kesseli; Kadiyala Ravindra; Lisa M McElroy; Andrew S Barbas Journal: In Vivo Date: 2020 Nov-Dec Impact factor: 2.155
Authors: Gysllene M C Brito; Andrea M M Fontenele; Erika Cristina R L Carneiro; Iara Antonia L Nogueira; Tamires B Cavalcante; André A M Vale; Sally Cristina M Monteiro; Natalino Salgado Filho Journal: Int J Inflam Date: 2021-06-23